"10.1371_journal.pone.0080528","plos one","2013-11-12T00:00:00Z","Christoph R Werner; Daniel P Egetemeyr; Ulrich M Lauer; Silvio Nadalin; Alfred Königsrainer; Nisar P Malek; Christoph P Berg","Medical Clinic, Department of Gastroenterology, Hepatology, and Infectiology, University Hospital Tuebingen, Tuebingen, Germany; Department of General, Visceral and Transplant Surgery, University Hospital Tuebingen, Tuebingen, Germany","Analyzed the data: CRW CPB DPE SN AK. Wrote the manuscript: CRW CPB DPE NPM UML.","The authors have read the journal’s policy and declare the following conflicts concerning Peg-Interferon alpha-2a (Roche), Peg-Interferon alpha-2b (Merck), Ribavirin (Roche, Merck), Telaprevir (Janssen-Cilag): CRW received travel grants from Merck, Roche, and Janssen-Cilag, and lecture fees from Roche, DPE received travel grants from Merck, and Roche, and lecture fees from Roche, UML received travel grants from Merck, and Roche, SN declares no conflict, AK declares no conflict, NPM declares no conflict, CPB received travel grants from Merck, Roche and Janssen-Cilag, and lecture fees from Merck, Roche, and Janssen-Cilag. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.","2013","11","Christoph R Werner","CRW",7,TRUE,NA,NA,5,5,TRUE,TRUE,FALSE,0,NA,FALSE
